Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi
Woman Max 99 years
Sanofi-Aventis recherche & de`veloppement
Update Il y a 4 ans
Multicenter, randomized, open label study evaluating a poly(ADP-ribose) polymerase-1(PARP-1) inhibitor, SAR240550 (BSI-201), administered twice weekly or weekly, in combination with gemcitabine/carboplatin, in patients with metastatic Triple Negative Breast Cancer (mTNBC)</
To assess the objective response rate (ORR) of SAR240550 administered as a 60min intravenous infusion twice weekly (arm A) or weekly (arm B), in combination with gemcitabine/carboplatin chemotherapy r...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Rt
Update Il y a 4 ans
The determination of the exact time of administration of Lantus basal insulin for treating type 2 diabetes mellitus patients poorly controlled with basal insulin associated with oral antidiabetic drugs
The determination of the exact time of administration of Lantus basal insulin.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Study of Sanofi Pasteur's dengue vaccine in Subjects Aged 2 to 45 Years in Mexico
Safety and reactogenicity Viremia Dengue immune responses
Country
None
organs
None
Specialty
None
More information
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
Sanofi-Aventis XALIP_C_02090 : Essai de phase 3 randomisé, en double aveugle, évaluant l’efficacité d’un traitement par xaliproden chez des patients ayant un cancer du colon, déjà traités par une chimiothérapie à base d’oxaliplatine. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A multi-center, randomized, double blind, placebo controlled phase iii study to assess the efficacy of xaliproden in patients with oxaliplatin-induced peripheral sensory neuropathy (PSN) following adj...
Country
France
organs
Côlon seul
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
A new vaccine for babies which adds protection against hepatitis B
To evaluate the concomitant administration of PR5I with two types of MCC vaccines (MCC-TT and MCC-CRM) to healthy infants at 3 and 4 months of age in term of antibody seroprotection rate (SPR) to MCC.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
A Study to Estimate the Immune Response Following a Challenge Dose in Adults (≥ 50 years old) Vaccinated With a Primary Series of an Hepatitis B Vaccine
To describe the Seroprotection rate (SPR) at least 2 years following completion of a primary series of modified process RECOMBIVAX HB™ ( HBVaxPRO) and 1 month following a challenge dose of modified pr...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
Combination therapy of insulin glargine and sitagliptin in patients with type 2 diabetes not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptin (Extension of the study LANTU_C_02761)
The study is the extension of the LANTU_C_02761 study (core study comparing insulin glargine versus sitagliptin in insulin-naïve patients treated with metformin and not adequately controlled). All pat...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi Pasteur Inc
Update Il y a 4 ans
A Phase II randomized, placebo-controlled, double-blind, dose ranging study of a Clostridium difficile toxoid vaccine (ACAM-CDIFF) in subjects with Clostridium difficile-associated infection(CDI)
To compare the event rate of CDI in groups assigned to ACAM-CDIFF vaccine (pooled groups) versus placebo in the 9 week period after the third dose of study vaccine (Study Days 29 to 91) in subjects wi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route)
1) To evaluate the compliance, in terms of immunogenicity, of the influenza vaccine (split virion, inactivated) NH 2010-2011 formulation with the requirements of the Committee for Proprietary Medicina...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
Comparison of three therapeutic strategies for treating type 2 diabetes mellitus patients poorly controlled with basal insulin associated with oral antidiabetic drugs
To show the non inferiority in terms of efficacy (HbA1c) of insulin glargine plus metformin combined with 1 to 3 bolus of insulin glulisine introduced progressively (Arm 2) compared with insulin glarg...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
9
10
11
12
13
14
15
16
17
18
Next